Related Experiment Video

Updated: Jul 10, 2026

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Perspectives of I(f) inhibition by ivabradine in cardiology

Michael Böhm1, Jan-Christian Reil

  • 1Klinik für Innere Medizin III (Kardiologie/Angiologie/Internistische Intensivmedizin), Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. boehm@med-in.uni-saarland.de

Drugs
|December 6, 2007
PubMed

Insights

High heart rates increase cardiovascular risks. Ivabradine, an If channel inhibitor, effectively lowers heart rate, potentially preventing heart disease complications and mortality in various patient groups.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Elevated heart rates are a significant predictor of cardiovascular morbidity and mortality across diverse populations, including healthy individuals, hypertensive patients, and those with established coronary heart disease (CHD) or heart failure.
  • Pharmacological heart rate reduction using If channel inhibition presents a therapeutic strategy to mitigate these risks and prevent cardiovascular complications.

Purpose of the Study:

  • To evaluate the efficacy of If channel inhibition with ivabradine in reducing heart rate and its impact on cardiovascular outcomes.
  • To assess the potential of ivabradine in preventing mortality and morbidity in patients with CHD and impaired left ventricular function or heart failure.

Main Methods:

  • Investigated the effects of If channel inhibition with ivabradine on heart rate.
  • Compared the antianginal effects of ivabradine with beta-adrenoceptor antagonists (beta-blockers) in patients with CHD.
  • Examined data from the BEAUTIfUL and SHIfT trials to determine ivabradine's impact on mortality and morbidity in specific patient cohorts.

Main Results:

  • Ivabradine demonstrates effective pharmacological heart rate reduction.
  • The antianginal effects of ivabradine are comparable to those of beta-blockers in patients with CHD.
  • Ongoing trials (BEAUTIfUL, SHIfT) are crucial for establishing ivabradine's role in reducing mortality and morbidity in heart failure and CHD patients.

Conclusions:

  • If channel inhibition with ivabradine is a promising therapeutic approach for heart rate management in cardiovascular disease.
  • Further research is warranted to explore ivabradine's potential in treating hypertension, atherosclerosis, and related complications.
  • Clarifying the pathophysiological mechanisms underlying heart rate reduction's benefits is essential for its broader application in cardiovascular interventions.

More Related Videos

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology10:41

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...